+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

GPCR-Targeting Therapies - Pipeline Insight, 2024

  • PDF Icon

    Drug Pipelines

  • 60 Pages
  • April 2024
  • Region: Global
  • DelveInsight
  • ID: 5951499
Description Jump to:

GPCR-Targeting Therapies Overview

GPCR-Targeting Therapies Pipeline Insight, 2024 report outlays comprehensive insights of present clinical development scenario and growth prospects across the GPCR-Targeting Therapies market. A detailed picture of the GPCR-Targeting Therapies pipeline landscape is provided, which includes the disease overview and GPCR-Targeting Therapies treatment guidelines. The assessment part of the report embraces in-depth GPCR-Targeting Therapies commercial assessment and clinical assessment of the GPCR-Targeting Therapies pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, GPCR-Targeting Therapies collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

GPCR-Targeting Therapies of Pipeline Development Activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of GPCR-Targeting Therapies with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the GPCR-Targeting Therapies treatment.
  • GPCR-Targeting Therapies key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of GPCR-Targeting Therapies market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

GPCR-Targeting Therapies Analytical Perspective

In-depth GPCR-Targeting Therapies Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

GPCR-Targeting Therapies Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.

Scope of the Report

  • The GPCR-Targeting Therapies report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GPCR-Targeting Therapies across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of GPCR-Targeting Therapies therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed GPCR-Targeting Therapies research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across GPCR-Targeting Therapies.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for GPCR-Targeting Therapies.
  • In the coming years, the GPCR-Targeting Therapies market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence GPCR-Targeting Therapies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the GPCR-Targeting Therapies treatment market. Several potential therapies for GPCR-Targeting Therapies are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the GPCR-Targeting Therapies market size in the coming years.
  • This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of GPCR-Targeting Therapies) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

  • What are the current options for GPCR-Targeting Therapies treatment?
  • How many companies are developing therapies for the treatment of GPCR-Targeting Therapies?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of GPCR-Targeting Therapies?
  • How many GPCR-Targeting Therapies emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of GPCR-Targeting Therapies?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact GPCR-Targeting Therapies market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of GPCR-Targeting Therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing GPCR-Targeting Therapies therapies?
  • What are the clinical studies going on for GPCR-Targeting Therapies and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for GPCR-Targeting Therapies?
  • How many patents are granted and pending for the emerging therapies for the treatment of GPCR-Targeting Therapies?


This product will be delivered within 1-3 business days.

Table of Contents

1. Report Introduction
2. GPCR-Targeting Therapies
2.1. Overview
2.2. History
2.3. GPCR-Targeting Therapies Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. GPCR-Targeting Therapies Diagnosis
2.6.1. Diagnostic Guidelines
3. GPCR-Targeting Therapies Current Treatment Patterns
3.1. GPCR-Targeting Therapies Treatment Guidelines
4. GPCR-Targeting Therapies - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. GPCR-Targeting Therapies companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. GPCR-Targeting Therapies Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. GPCR-Targeting Therapies Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. GPCR-Targeting Therapies Late Stage Products (Phase-III)7. GPCR-Targeting Therapies Mid Stage Products (Phase-II)8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products12. GPCR-Targeting Therapies Discontinued Products
13. GPCR-Targeting Therapies Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report14. GPCR-Targeting Therapies Key Companies15. GPCR-Targeting Therapies Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. GPCR-Targeting Therapies Unmet Needs18. GPCR-Targeting Therapies Future Perspectives19. GPCR-Targeting Therapies Analyst Review20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
List of Tables
Table 1: GPCR-Targeting Therapies Diagnostic Guidelines
Table 2: GPCR-Targeting Therapies Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: GPCR-Targeting Therapies Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: GPCR-Targeting Therapies Late Stage Products (Phase-III)
Table 18: GPCR-Targeting Therapies mid Stage Products (Phase-II)
Table 19: GPCR-Targeting Therapies Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
List of Figures
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: GPCR-Targeting Therapies companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: GPCR-Targeting Therapies Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs

Related Topics

Related Products

Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2024 - Product Image

Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
CCR8-Targeted Antibody Immunotherapy Pipeline Review - Product Image

CCR8-Targeted Antibody Immunotherapy Pipeline Review

  • Report
  • Global
From
TCR-Therapy - Pipeline Insight, 2024 - Product Image

TCR-Therapy - Pipeline Insight, 2024

  • Drug Pipelines
  • 190 Pages
  • Global
From
Oncolytic Virus Cancer Therapy Pipeline Analysis Report - Product Image

Oncolytic Virus Cancer Therapy Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.